JNJ · NYSE · CIK 0000200406
Johnson & Johnson
Johnson & Johnson holds 15 disclosed positions, 15 of them carrying a sourced value.
Share price
JNJ
Equity stakes Johnson & Johnson holds in other companies.
modelled, reported or pending
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 4,565 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
4,565 managers reported a position, together holding 1.77bn shares, or 73.5% of the company. The 40 largest are listed.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Johnson & Johnson has no founder or dual-class structure; it is a widely held, single-class company with no controlling shareholder. The individual insider positions listed (Duato, Taubert, Wolk, Schmid) are the Named Executive Officers with the largest holdings, not a controlling stake: even the full 21-person group of directors and executive officers holds under 0.2% of shares outstanding.
- The register's institutional rows (Vanguard, BlackRock, State Street, JPMorgan, Geode, Morgan Stanley) are taken from the pre-built 13F-derived register at data/registers/JNJ.json (period 31-MAR-2026), not re-derived. Only a curated subset of that register's 40 rows is reproduced here, per the brief.
- JNJ's own Q2 2026 10-Q reports total equity investments of $803m with readily determinable fair value and $832m without readily determinable fair value (non-marketable, mostly private JJDC venture stakes), but does not itemize either bucket by issuer. The 15 holdings listed above are the itemized, readily-determinable-value slice: they came instead from JNJ's own Form 13F-HR (period 30 Jun 2026), which totals $798,650,757 across those 15 public issuers, closely reconciling with the 10-Q's $803m readily-determinable-value figure (the small gap is normal 13F/10-Q valuation-date and methodology differences).
- All 15 holdings are managed by Johnson & Johnson Innovation - JJDC, Inc. (JJDC), JNJ's corporate venture capital arm; JJDC's public positions are reported on JNJ's own 13F-HR rather than a separate JJDC filer CIK.
- Legend Biotech (LEGN) is a JJDC equity stake, distinct from JNJ's separate, larger commercial collaboration and cost-sharing agreement with Legend's Carvykti cell therapy; only the equity stake is captured here as a holding.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- The $832m of JNJ equity investments without readily determinable fair value (mostly private, pre-IPO JJDC venture stakes) is not broken out by investee name anywhere in the Q2 2026 10-Q or any other filing found; no private-company holdings could be itemized for this file. Searched: the 10-Q's Note on Equity Investments (search terms 'equity investments', 'non-marketable', 'equity method', 'strategic investment') and EDGAR full-text search for 13D/13G filings referencing JJDC (none since Nov 2024).
- pct_of_target for the 15 JJDC public holdings could not be sourced: each would require that issuer's own current shares-outstanding figure, and JJDC's own Schedule 13D/G filings on these names are all from 2024 or earlier (stale relative to the Jun 2026 13F share counts), so no current percentage was modelled rather than use a mismatched denominator.
- No SC 13D/13G filings by JNJ or JJDC have been made since November 2024 despite JJDC still holding >5% stakes in several small-cap names per the 13F (e.g. Contineum, Rapport, MeiraGTx); could not confirm from a primary source whether ownership has fallen under reporting thresholds or whether required amendments are simply outstanding.
- JPMorgan Chase & Co. and Geode Capital Management's exact 13F filing URLs were not individually re-fetched (values taken as-is from the pre-built data/registers/JNJ.json per the brief's instruction not to re-derive the register); their as_of date is inherited from that register's period (31-MAR-2026).